IIL to invest Rs 250 crore in new plant
The unit can produce an estimated 300 million tablets and 100 million bolus
By : DC Correspondent
Update: 2015-10-27 01:00 GMT
Hyderabad: Indian Immunologicals Limited (IIL), a leading biologicals company, plans to invest Rs 250 crore in its new state-of-the-art facility at Karkapatla, Ranga Reddy district, Telangana.
The unit, spread across 47 acres at Phase III of Genome Valley, Karkapatla, is IIL’s second manufacturing unit in Hyderabad. It has been established to manufacture vaccines against infectious diseases of humans and animal health formulations catering to domestic as well as international markets.
Indian Immunologicals Limited deputy MD Dr K. Anand Kumar said, “The facility will strengthen IIL’s position in the industry and will immensely increase our manufacturing capabilities.” The unit can produce an estimated 300 million tablets and 100 million bolus.